- Home
- EDTK vs IGC Comparison
EDTK vs IGC Comparison
Compare EDTK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- IGC
- Stock Information
- Founded
- EDTK 2013
- IGC 2005
- Country
- EDTK China
- IGC United States
- Employees
- EDTK N/A
- IGC N/A
- Industry
- EDTK Other Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- IGC Health Care
- Exchange
- EDTK Nasdaq
- IGC Nasdaq
- Market Cap
- EDTK 16.2M
- IGC 19.1M
- IPO Year
- EDTK 2020
- IGC N/A
- Fundamental
- Price
- EDTK $1.01
- IGC $0.27
- Analyst Decision
- EDTK
- IGC Strong Buy
- Analyst Count
- EDTK 0
- IGC 2
- Target Price
- EDTK N/A
- IGC $3.88
- AVG Volume (30 Days)
- EDTK 6.5K
- IGC 349.0K
- Earning Date
- EDTK 04-11-2025
- IGC 02-18-2025
- Dividend Yield
- EDTK N/A
- IGC N/A
- EPS Growth
- EDTK N/A
- IGC N/A
- EPS
- EDTK N/A
- IGC N/A
- Revenue
- EDTK $624,365.00
- IGC $1,236,000.00
- Revenue This Year
- EDTK N/A
- IGC N/A
- Revenue Next Year
- EDTK N/A
- IGC $18.34
- P/E Ratio
- EDTK N/A
- IGC N/A
- Revenue Growth
- EDTK N/A
- IGC 1.65
- 52 Week Low
- EDTK $0.84
- IGC $0.26
- 52 Week High
- EDTK $1.27
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- EDTK 46.53
- IGC 36.04
- Support Level
- EDTK $0.99
- IGC $0.29
- Resistance Level
- EDTK $1.03
- IGC $0.32
- Average True Range (ATR)
- EDTK 0.04
- IGC 0.02
- MACD
- EDTK -0.00
- IGC -0.00
- Stochastic Oscillator
- EDTK 41.98
- IGC 6.25
Stock Price Comparison Chart: EDTK vs IGC
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.